Research location
Pruszków
Poland
Advertisement
Research activity in Pruszków
PolandCureCurrent currently publishes aggregate city-level research activity for this location: 16 trials and 16 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Pruszków
16 linked trials · page 1 of 1A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)NCT06883305 · 2025-03-18 · 1 site observation
RECRUITING
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressureNCT06742723 · 2025-03-03 · 1 site observation
RECRUITING
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of ExacerbationsNCT06040086 · 2023-09-22 · 1 site observation
COMPLETED
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of SchizophreniaNCT04531982 · 2020-08-05 · 1 site observation
COMPLETED
Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant DepressionNCT03965858 · 2019-02-25 · 1 site observation
COMPLETED
A Study of Paliperidone Palmitate 6-Month FormulationNCT03345342 · 2017-11-20 · 1 site observation
COMPLETED
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideNCT03097133 · 2017-06-15 · 1 site observation
COMPLETED
Extension Study of Pimavanserin for the Adjunctive Treatment of SchizophreniaNCT03121586 · 2017-01-01 · 1 site observation
TERMINATED
Effect of Lu AF35700 in Patients With Treatment-resistant SchizophreniaNCT02717195 · 2016-04-01 · 1 site observation
COMPLETED
Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 DiabetesNCT01045707 · 2010-01-01 · 1 site observation
COMPLETED
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With SchizophreniaNCT00731549 · 2008-12-01 · 1 site observation
COMPLETED
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With SchizophreniaNCT00706654 · 2008-09-01 · 1 site observation
COMPLETED
Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive DisorderNCT00707980 · 2008-06-01 · 1 site observation
COMPLETED
Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.NCT00563381 · 2008-01-01 · 1 site observation
COMPLETED
A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 DiabetesNCT00672386 · 2007-12-01 · 1 site observation
COMPLETED
Olmesartan Medoxomil and Diabetic NephropathyNCT00362960 · 2003-05-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.